ReviewJournal of clinical and experimental hepatology2017
Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.
Review in Journal of clinical and experimental hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- The Association Between Cytomegalovirus Infection and Kidney Damage in the Liver Transplant Setting.Viruses · 2024Article
- Pneumonia in Transplant Recipients: A Comprehensive Review of Diagnosis and Management.Cureus · 2024Review
- Management of cytomegalovirus infection after liver transplantation.World journal of transplantation · 2024Review
- Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation.Viruses · 2022Article
- Cytomegalovirus infection in liver-transplanted children.World journal of hepatology · 2022Review
- Inhibiting cytomegalovirus replication through targeting the host electron transport chain.Antiviral research · 2021Article
- Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2021Article
- Cytomegalovirus Hepatitis in Immunocompetent and Immunocompromised Hosts.Journal of clinical and translational hepatology · 2021Review
- Encephalopathy Associated with Severe Cytomegalovirus Infection in an Immunocompetent Young Woman.Case reports in infectious diseases · 2021Article
- Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers.Journal of clinical medicine · 2020Article
- Vaccination against the human cytomegalovirus.Vaccine · 2019Review
- Ganciclovir-Resistant CMV Colitis in a Donor-Seronegative/Recipient-Seronegative Liver Transplant Patient.ACG case reports journal · 2018Article
- Infections After Liver Transplant -Timeline, Management and Prevention.Journal of clinical and experimental hepatologyReview
- Cytomegalovirus Duodenitis Causing Persistent Hypoalbuminemia and Ascites After Liver Transplantation.Journal of clinical and experimental hepatologyArticle
- Long Term Complications of Immunosuppression Post Liver Transplant.Journal of clinical and experimental hepatologyArticle
- Oral ulcerative lesions in a post-liver-transplantation patient.Autopsy & case reportsArticle
- Post liver transplant recurrent and de novo viral infections.Best practice & research. Clinical gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) infection is the most common viral infection in liver transplant recipients, affecting post-transplant patients and graft survival. Recent advances in diagnosis and management of CMV have led to marked reduction in incidence, severity, and its associated morbidity and mortality. CMV DNA assay is the most commonly used laboratory parameter to diagnose and monitor CMV infection. Current evidence suggests that both pre-emptive and universal prophylaxis approaches are equally justified in liver transplant recipients. Intravenous ganciclovir and oral valganciclovir are the most commonly used drugs for treatment of CMV disease. Most of the centre use valganciclovir prophylaxis for prevention of CMV disease in liver trasplant recipient. The aim of this article is to review the current standard of care for diagnosis and management of CMV disease in liver transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.